The Role of Plasminogen Activator Inhibitor-1 Polymorphism, Factor-V-Leiden, and Prothrombin-20210 Mutations in Pulmonary Thromboembolism


Creative Commons License

OĞUZÜLGEN İ. K. , Demirtas S., Erkekol F. O. , Ekim N., Demir N., Numanoglu N., ...More

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.15, no.1, pp.73-77, 2009 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 1
  • Publication Date: 2009
  • Doi Number: 10.1177/1076029607305110
  • Title of Journal : CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
  • Page Numbers: pp.73-77

Abstract

Polymorphism in plasminogen activator inhibitor-1 gene is suggested to be associated with an increased risk of venous thromboembolism. The aim of this study was to investigate the association of plasminogen activator inhibitor-1 gene polymorphism and its coexistence with factor-V-Leiden and prothrombin-20210 mutations in pulmonary thromboembolism. The authors investigated plasminogen activator inhibitor-1 4G/5G polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in 143 pulmonary thromboembolism patients and 181 controls. Plasminogen activator inhibitor-1 4G/4G, 4G/5G, and 5G/5G gene polymorphisms and prothrombin-20210 mutations were not different between cases and controls. Factor-V-Leiden mutation was present in 21.0% and 7.7% of the cases and controls, respectively, P = .001. Neither different plasminogen activator inhibitor-1 genotypes and 4G allele nor coexistence of the allele with factor-V-Leiden or prothrombin-20210 was associated with the risk of recurrence. As a result, plasminogen activator inhibitor-1 gene polymorphism or its concomitant presence with mentioned mutations was not found to be associated with increased risk for pulmonary thromboembolism or recurrent disease in this study.